



Drug Use Research & Management Program
 DHS - Health Systems Division
 500 Summer Street NE, E35, Salem, OR 97301-1079
 Phone 503-947-5220 | Fax 503-947-1119

College of Pharmacy

Pharmacy Utilization Summary Report: January 2024 - December 2024

Eligibility	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Avg Monthly
Total Members (FFS & Encounter)	1,276,290	1,264,099	1,268,663	1,249,346	1,239,354	1,231,095	1,226,816	1,235,264	1,241,007	1,247,678	1,254,503	1,257,986	1,249,342
FFS Members	118,187	112,962	110,868	105,128	103,204	102,443	98,771	97,509	96,865	99,056	99,856	98,868	103,643
OHP Basic with Medicare	9,270	9,176	9,007	8,737	8,820	8,839	8,606	8,437	8,250	8,222	7,915	7,437	8,560
OHP Basic without Medicare	9,779	9,707	9,663	9,533	9,402	9,417	9,308	9,241	9,221	9,278	9,034	8,899	9,374
ACA	99,138	94,079	92,198	86,858	84,982	84,187	80,857	79,831	79,394	81,556	82,907	82,532	85,710
Encounter Members	1,158,103	1,151,137	1,157,795	1,144,218	1,136,150	1,128,652	1,128,045	1,137,755	1,144,142	1,148,622	1,154,647	1,159,118	1,145,699
OHP Basic with Medicare	104,359	105,114	106,811	106,369	106,771	106,835	107,175	107,413	106,294	103,103	98,130	90,342	103,976
OHP Basic without Medicare	67,029	67,008	67,065	67,120	66,762	66,760	66,835	66,785	66,566	66,469	66,271	65,605	66,690
ACA	986,715	979,015	984,919	970,729	962,617	955,057	954,035	963,557	971,282	979,050	990,246	1,003,171	975,033

Gross Cost Figures for Drugs	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	YTD Sum
Total Amount Paid (FFS & Encounter)	\$126,309,749	\$118,753,666	\$123,344,857	\$128,383,849	\$134,174,541	\$121,193,472	\$132,304,382	\$130,506,517	\$128,362,891	\$141,569,047	\$126,978,471	\$139,368,773	\$1,551,250,216
Mental Health Carve-Out Drugs	\$10,671,443	\$9,904,775	\$10,223,544	\$10,728,919	\$10,949,674	\$10,274,511	\$11,184,598	\$10,963,354	\$10,706,736	\$12,019,617	\$10,903,459	\$12,718,407	\$131,249,037
OHP Basic with Medicare	\$2,241	\$126	\$7,048	\$6,918	\$10,164	\$13,561	\$3,422	\$73	\$6,729	\$10,123	\$9,428	\$1,297	\$71,131
OHP Basic without Medicare	\$3,903,775	\$3,576,290	\$3,562,132	\$3,840,988	\$3,850,740	\$3,671,253	\$3,907,930	\$3,912,162	\$3,676,992	\$4,140,377	\$3,648,373	\$4,219,988	\$45,911,000
ACA	\$6,324,214	\$5,815,292	\$6,253,183	\$6,405,522	\$6,605,119	\$6,178,857	\$6,809,566	\$6,643,787	\$6,599,085	\$7,368,982	\$6,791,265	\$7,948,436	\$79,743,308
FFS Physical Health Drugs	\$2,965,591	\$2,634,190	\$2,567,733	\$2,585,546	\$2,393,813	\$2,307,256	\$2,642,330	\$2,362,638	\$2,397,059	\$2,286,198	\$1,838,506	\$2,224,083	\$29,204,942
OHP Basic with Medicare	\$38,658	\$33,635	\$32,795	\$31,589	\$35,640	\$31,427	\$32,230	\$29,420	\$27,899	\$30,256	\$27,471	\$28,979	\$380,000
OHP Basic without Medicare	\$1,024,627	\$852,331	\$872,265	\$839,973	\$822,877	\$775,023	\$903,285	\$761,140	\$736,750	\$732,436	\$544,391	\$661,258	\$9,526,356
ACA	\$1,657,626	\$1,504,677	\$1,424,866	\$1,417,647	\$1,297,929	\$1,292,910	\$1,512,301	\$1,416,133	\$1,409,101	\$1,330,551	\$1,067,046	\$1,283,386	\$16,614,174
FFS Physician Administered Drugs	\$2,130,579	\$1,552,483	\$1,548,395	\$1,415,221	\$1,114,920	\$1,290,537	\$1,303,730	\$1,523,346	\$925,710	\$1,359,821	\$1,649,044	\$1,244,989	\$17,058,775
OHP Basic with Medicare	\$204,370	\$189,728	\$99,263	\$150,964	\$106,708	\$130,433	\$128,030	\$160,459	\$131,673	\$134,017	\$97,510	\$123,264	\$1,656,418
OHP Basic without Medicare	\$274,292	\$337,079	\$296,179	\$267,064	\$215,197	\$491,581	\$192,566	\$295,895	\$53,454	\$313,663	\$432,161	\$191,554	\$3,360,685
ACA	\$964,511	\$530,953	\$568,586	\$383,991	\$357,896	\$328,452	\$422,477	\$483,778	\$466,362	\$500,468	\$640,578	\$526,555	\$6,174,606
Encounter Physical Health Drugs	\$83,357,004	\$78,166,408	\$82,091,837	\$86,153,643	\$88,026,704	\$79,086,463	\$88,419,122	\$87,211,023	\$87,230,923	\$94,568,241	\$85,622,728	\$92,639,641	\$1,032,573,737
OHP Basic with Medicare	\$401,914	\$385,646	\$414,949	\$387,864	\$375,701	\$370,301	\$391,026	\$390,476	\$397,947	\$429,504	\$352,755	\$334,852	\$4,632,935
OHP Basic without Medicare	\$18,434,142	\$16,795,756	\$17,668,823	\$18,650,239	\$19,017,323	\$17,219,252	\$19,385,247	\$19,038,566	\$18,254,021	\$19,946,108	\$17,890,817	\$19,443,313	\$221,743,605
ACA	\$55,717,308	\$51,254,547	\$54,052,158	\$56,262,565	\$57,521,542	\$51,565,967	\$57,164,124	\$56,671,132	\$57,559,492	\$61,600,144	\$56,164,908	\$61,002,953	\$676,536,839
Encounter Physician Administered Drugs	\$27,185,131	\$26,495,810	\$26,913,348	\$27,500,520	\$31,689,430	\$28,234,705	\$28,754,602	\$28,446,156	\$27,102,464	\$31,335,171	\$26,964,734	\$30,541,653	\$341,163,724
OHP Basic with Medicare	\$1,425,625	\$1,312,518	\$1,152,883	\$1,184,813	\$1,190,621	\$1,042,888	\$1,107,368	\$1,011,085	\$983,778	\$1,093,059	\$774,536	\$809,764	\$13,088,937
OHP Basic without Medicare	\$5,064,547	\$5,568,443	\$5,565,171	\$5,900,654	\$5,711,579	\$5,412,813	\$6,256,485	\$6,150,401	\$5,444,512	\$6,341,122	\$5,317,934	\$5,737,427	\$68,471,088
ACA	\$16,961,314	\$16,132,416	\$16,351,162	\$16,977,122	\$21,253,231	\$18,794,996	\$18,058,274	\$17,827,086	\$16,969,300	\$19,854,587	\$17,669,882	\$19,661,699	\$216,511,068

OHP = Oregon Health Plan

ACA = Affordable Care Act expansion



Amount Paid on the Claim = 1) Ingredient Cost ((AAAC/NADAC/WAC) x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount

Last Updated: August 28, 2025



Pharmacy Utilization Summary Report: January 2024 - December 2024

YTD Percent Paid Amounts




OHP = Oregon Health Plan
ACA = Affordable Care Act expansion
PAD = Physician-administered drugs
Amount Paid on the Claim = 1) Ingredient Cost ((AAAC/NADAC/WAC) x Dispense Quantity) + Dispensing Fee.
If Billed Amount is lower, pay Billed Amount, 2) - TPL amount



Pharmacy Utilization Summary Report: January 2024 - December 2024

Quarterly Rebates Invoiced	2024-Q1	2024-Q2	2024-Q3	2024-Q4	YTD Sum
Total Rebate Invoiced (FFS & Encounter)	\$132,002,520	\$127,539,316	\$121,797,092	\$127,663,604	\$509,002,533
CMS MH Carve-out	\$11,879,437	\$11,690,323	\$11,615,225	\$12,292,512	\$47,477,497
SR MH Carve-out	\$2,369,032	\$2,860,832	\$2,919,188	\$3,356,035	\$11,505,087
CMS FFS Drug	\$5,125,198	\$4,213,833	\$4,307,265	\$3,406,149	\$17,052,445
SR FFS	\$679,922	\$634,385	\$508,558	\$481,944	\$2,304,810
CMS Encounter	\$107,988,242	\$104,856,037	\$99,229,938	\$104,103,210	\$416,177,427
SR Encounter	\$3,960,688	\$3,283,906	\$3,216,918	\$4,023,755	\$14,485,267

Quarterly Net Drug Costs	2024-Q1	2024-Q2	2024-Q3	2024-Q4	YTD Sum
Estimated Net Drug Costs (FFS & Encounter)	\$236,405,752	\$256,212,546	\$269,376,698	\$280,252,687	\$1,042,247,683
Mental Health Carve-Out Drugs	\$16,551,293	\$17,401,949	\$18,320,274	\$19,992,938	\$72,266,453
FFS Phys Health + PAD	\$7,593,852	\$6,259,075	\$6,338,989	\$6,714,546	\$26,906,462
Encounter Phys Health + PAD	\$212,260,608	\$232,551,522	\$244,717,435	\$253,545,203	\$943,074,768



SR = Supplemental Rebate
 CMS = Center for Medicaid Services
 PAD = Physician-administered drugs
 MH = Mental Health



Pharmacy Utilization Summary Report: January 2024 - December 2024

Gross PMPM Drug Costs (Rebates not Subtracted)	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Avg Monthly
PMPM Amount Paid (FFS & Encounter)	\$98.97	\$93.94	\$97.22	\$102.76	\$108.26	\$98.44	\$107.84	\$105.65	\$103.43	\$113.47	\$101.22	\$110.79	\$103.50
Mental Health Carve-Out Drugs	\$8.36	\$7.84	\$8.06	\$8.59	\$8.83	\$8.35	\$9.12	\$8.88	\$8.63	\$9.63	\$8.69	\$10.11	\$8.76
FFS Physical Health Drugs	\$25.09	\$23.32	\$23.16	\$24.59	\$23.19	\$22.52	\$26.75	\$24.23	\$24.75	\$23.08	\$18.41	\$22.50	\$23.47
FFS Physician Administered Drugs	\$18.03	\$13.74	\$13.97	\$13.46	\$10.80	\$12.60	\$13.20	\$15.62	\$9.56	\$13.73	\$16.51	\$12.59	\$13.65
Encounter Physical Health Drugs	\$71.98	\$67.90	\$70.90	\$75.29	\$77.48	\$70.07	\$78.38	\$76.65	\$76.24	\$82.33	\$74.15	\$79.92	\$75.11
Encounter Physician Administered Drugs	\$23.47	\$23.02	\$23.25	\$24.03	\$27.89	\$25.02	\$25.49	\$25.00	\$23.69	\$27.28	\$23.35	\$26.35	\$24.82
Claim Counts	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Avg Monthly
Total Claim Count (FFS & Encounter)	1,274,048	1,222,538	1,273,554	1,312,044	1,326,342	1,213,395	1,279,910	1,251,432	1,238,791	1,339,778	1,233,915	1,319,010	1,273,730
Mental Health Carve-Out Drugs	216,802	201,348	208,991	213,459	214,277	196,678	213,437	208,214	205,061	222,000	204,382	221,208	210,488
FFS Physical Health Drugs	33,912	31,576	32,463	32,213	31,783	27,847	28,211	25,559	25,263	26,873	24,295	26,405	28,867
FFS Physician Administered Drugs	10,118	9,766	9,955	9,234	9,614	8,680	8,786	8,273	8,027	8,278	7,225	7,674	8,803
Encounter Physical Health Drugs	886,991	853,575	889,346	920,244	931,509	851,795	895,803	876,950	872,641	941,787	866,338	926,810	892,816
Encounter Physician Administered Drugs	126,225	126,273	132,799	136,894	139,159	128,395	133,673	132,436	127,799	140,840	131,675	136,913	132,757
Gross Amount Paid per Claim (Rebates not Subtracted)	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Avg Monthly
Average Paid / Claim (FFS & Encounter)	\$99.14	\$97.14	\$96.85	\$97.85	\$101.16	\$99.88	\$103.37	\$104.29	\$103.62	\$105.67	\$102.91	\$105.66	\$101.46
Mental Health Carve-Out Drugs	\$49.22	\$49.19	\$48.92	\$50.26	\$51.10	\$52.24	\$52.40	\$52.65	\$52.21	\$54.14	\$53.35	\$57.50	\$51.93
FFS Physical Health Drugs	\$87.45	\$83.42	\$79.10	\$80.26	\$75.32	\$82.85	\$93.66	\$92.44	\$94.88	\$85.07	\$75.67	\$84.23	\$84.53
FFS Physician Administered Drugs	\$210.57	\$158.97	\$155.54	\$153.26	\$115.97	\$148.68	\$148.39	\$184.13	\$115.32	\$164.27	\$228.24	\$162.23	\$162.13
Encounter Physical Health Drugs	\$93.98	\$91.58	\$92.31	\$93.62	\$94.50	\$92.85	\$98.70	\$99.45	\$99.96	\$100.41	\$98.83	\$99.96	\$96.35
Encounter Physician Administered Drugs	\$215.37	\$209.83	\$202.66	\$200.89	\$227.72	\$219.91	\$215.11	\$214.79	\$212.07	\$222.49	\$204.78	\$223.07	\$214.06
Gross Amount Paid per Claim - Generic-Multi Source Drugs (Rebates not Subtracted)	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Avg Monthly
Generic-Multi Source Drugs: Average Paid / Claim (FFS & Encounter)	\$21.15	\$20.97	\$21.43	\$22.13	\$22.20	\$21.91	\$22.69	\$22.85	\$22.86	\$22.56	\$22.11	\$22.30	\$22.10
Mental Health Carve-Out Drugs	\$14.23	\$14.19	\$14.19	\$14.20	\$14.26	\$14.13	\$14.10	\$14.05	\$13.96	\$13.94	\$13.90	\$15.30	\$14.21
FFS Physical Health Drugs	\$25.55	\$24.59	\$24.88	\$24.04	\$23.63	\$23.40	\$21.65	\$23.78	\$24.71	\$21.59	\$21.61	\$20.79	\$23.35
Encounter Physical Health Drugs	\$22.82	\$22.56	\$23.14	\$24.04	\$24.11	\$23.80	\$24.93	\$25.08	\$25.10	\$24.81	\$24.23	\$24.14	\$24.06
Gross Amount Paid per Claim - Branded-Single Source Drugs (Rebates not Subtracted)	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Avg Monthly
Branded-Single Source Drugs: Average Paid / Claim (FFS & Encounter)	\$767.64	\$762.62	\$774.38	\$786.10	\$794.75	\$776.22	\$813.48	\$802.10	\$713.21	\$726.49	\$752.57	\$816.93	\$773.87
Mental Health Carve-Out Drugs	\$1,394.53	\$1,397.30	\$1,410.14	\$1,437.96	\$1,446.06	\$1,466.19	\$1,441.36	\$1,446.23	\$1,432.91	\$1,473.45	\$1,462.77	\$1,511.42	\$1,443.36
FFS Physical Health Drugs	\$469.74	\$461.00	\$447.54	\$468.25	\$430.28	\$466.32	\$537.30	\$500.63	\$457.93	\$473.29	\$421.12	\$501.47	\$469.57
Encounter Physical Health Drugs	\$744.35	\$738.91	\$751.36	\$760.47	\$770.64	\$746.68	\$784.65	\$773.36	\$683.64	\$692.61	\$721.68	\$782.06	\$745.87
Generic Drug Use Percentage	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Avg Monthly
Generic Drug Use Percentage	91.4%	91.6%	91.7%	91.7%	91.7%	91.6%	91.5%	91.3%	90.1%	90.2%	90.7%	91.3%	91.2%
Mental Health Carve-Out Drugs	97.5%	97.5%	97.5%	97.5%	97.4%	97.4%	97.3%	97.3%	97.3%	97.2%	97.3%	97.2%	97.4%
FFS Physical Health Drugs	86.1%	86.5%	87.2%	87.3%	87.3%	86.6%	86.0%	85.6%	83.8%	85.9%	86.5%	86.8%	86.3%
Encounter Physical Health Drugs	90.1%	90.4%	90.5%	90.6%	90.6%	90.4%	90.3%	90.1%	88.6%	88.7%	89.3%	90.0%	90.0%
Preferred Drug Use Percentage	Jan-24	Feb-24	Mar-24	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Avg Monthly
Preferred Drug Use Percentage	89.96%	89.95%	90.00%	89.97%	89.92%	89.85%	88.89%	88.58%	88.53%	88.48%	88.42%	88.34%	89.2%
Mental Health Carve-Out Drugs	92.69%	92.59%	92.67%	92.53%	92.48%	92.38%	86.70%	86.66%	86.50%	86.49%	86.51%	86.35%	89.5%
FFS Physical Health Drugs	94.81%	94.65%	94.61%	94.48%	94.61%	94.60%	94.53%	94.59%	94.32%	94.48%	94.67%	94.56%	94.6%
Encounter Physical Health Drugs	89.16%	89.19%	89.24%	89.25%	89.21%	89.15%	89.27%	88.89%	88.88%	88.82%	88.73%	88.68%	89.0%

Amount Paid on the Claim = 1) Ingredient Cost ((AAAC/NADAC/WAC) x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount



Top 40 Drugs by Gross Amount Paid (FFS Only) - Second Quarter 2025

Rank	Drug	PDL Class	Amount Paid	% Total FFS Costs	Claim Count	Avg Paid per Claim	PDL
1	VRAYLAR*	Antipsychotics, 2nd Gen	\$6,442,759	12.5%	4,713	\$1,367	Y
2	INVEGA SUSTENNA	Antipsychotics, Parenteral	\$5,708,601	11.1%	2,088	\$2,734	Y
3	REXULTI*	Antipsychotics, 2nd Gen	\$3,284,618	6.4%	2,358	\$1,393	V
4	ABILIFY MAINTENA	Antipsychotics, Parenteral	\$2,983,585	5.8%	1,208	\$2,470	Y
5	CAPLYTA*	Antipsychotics, 2nd Gen	\$1,784,166	3.5%	1,217	\$1,466	V
6	SPRAVATO*	Antidepressants	\$1,663,110	3.2%	1,246	\$1,335	V
7	INVEGA TRINZA	Antipsychotics, Parenteral	\$1,487,946	2.9%	181	\$8,221	Y
8	ARISTADA	Antipsychotics, Parenteral	\$1,104,465	2.1%	426	\$2,593	Y
9	TRINTELLIX	Antidepressants	\$1,071,738	2.1%	2,285	\$469	V
10	AUVELITY	Antidepressants	\$893,279	1.7%	928	\$963	V
11	BUPROPION XL	Antidepressants	\$804,710	1.6%	59,279	\$14	Y
12	LYBALVI*	Antipsychotics, 2nd Gen	\$767,290	1.5%	517	\$1,484	V
13	SERTRALINE HCL	Antidepressants	\$732,244	1.4%	64,779	\$11	Y
14	ABILIFY ASIMTUFII	Antipsychotics, Parenteral	\$729,658	1.4%	138	\$5,287	Y
15	TRAZODONE HCL	Antidepressants	\$669,785	1.3%	54,827	\$12	V
16	FLUOXETINE HCL	Antidepressants	\$638,167	1.2%	51,138	\$12	Y
17	ESCITALOPRAM OXALATE	Antidepressants	\$629,036	1.2%	50,117	\$13	Y
18	DULOXETINE HCL	Antidepressants	\$624,480	1.2%	41,208	\$15	Y
19	QELBREE*	ADHD Drugs	\$541,298	1.1%	1,165	\$465	Y
20	BUSPIRONE HCL	STC 07 - Ataractics, Tranquilizers	\$430,489	0.8%	32,245	\$13	
21	Inj, Nusinersen, 0.1mg	Physican Administered Drug	\$410,166	0.8%	3	\$136,722	
22	LAMOTRIGINE	Antiepileptics, Outpatient	\$402,237	0.8%	32,222	\$12	Y
23	INVEGA HAFYERA	Antipsychotics, Parenteral	\$371,978	0.7%	21	\$17,713	Y
24	Inj Pembrolizumab	Physican Administered Drug	\$362,049	0.7%	58	\$6,242	
25	ARIPIRAZOLE*	Antipsychotics, 2nd Gen	\$351,070	0.7%	23,555	\$15	Y
26	BIKTARVY	HIV	\$343,627	0.7%	113	\$3,041	Y
27	BUPROPION XL	Antidepressants	\$293,123	0.6%	1,908	\$154	V
28	QUETIAPINE FUMARATE*	Antipsychotics, 2nd Gen	\$288,098	0.6%	22,392	\$13	Y
29	ATOMOXETINE HCL*	ADHD Drugs	\$274,280	0.5%	10,915	\$25	Y
30	VENLAFAXINE HCL ER	Antidepressants	\$256,403	0.5%	19,134	\$13	Y
31	MAVYRET*	Hepatitis C, Direct-Acting Antivirals	\$227,943	0.4%	22	\$10,361	Y
32	SERTRALINE HCL	Antidepressants	\$227,689	0.4%	1,455	\$156	V
33	SUBLOCADE	Substance Use Disorders, Opioid & Alcohol	\$221,094	0.4%	115	\$1,923	Y
34	COBENFY*	Antipsychotics, 2nd Gen	\$218,699	0.4%	139	\$1,573	V
35	RISPERDAL CONSTA*	Antipsychotics, Parenteral	\$214,054	0.4%	189	\$1,133	Y
36	MIRTAZAPINE	Antidepressants	\$212,779	0.4%	14,532	\$15	Y
37	UZEDY	Antipsychotics, Parenteral	\$211,355	0.4%	71	\$2,977	Y
38	OLANZAPINE*	Antipsychotics, 2nd Gen	\$207,097	0.4%	14,514	\$14	Y
39	GUANFACINE HCL ER	ADHD Drugs	\$199,723	0.4%	14,144	\$14	Y
40	OZEMPIC*	Diabetes, GLP-1 Receptor Agonists and GIP The	\$191,960	0.4%	352	\$545	N
Top 40 Aggregate:			\$38,476,846		527,917	\$5,325	
All FFS Drugs Totals:			\$51,514,486		794,835	\$647	

* Drug requires Prior Authorization

Notes

- FFS Drug Gross Costs only, rebates not subtracted
- PDL Key: Y=Preferred, N=Non-Preferred, V=Voluntary, Blank=Non PDL Class
- Amount Paid on the Claim = 1) Ingredient Cost ((AAAC/NADAC/WAC) x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount



Top 40 Physical Health Drugs by Gross Amount Paid (FFS Only) - Second Quarter 2025

Rank	Drug	PDL Class	Amount Paid	% Total FFS Costs	Claim Count	Avg Paid per Claim	PDL
1	Inj, Nusinersen, 0.1mg	Physican Administered Drug	\$410,166	4.0%	3	\$136,722	
2	Inj Pembrolizumab	Physican Administered Drug	\$362,049	3.5%	58	\$6,242	
3	BIKTARVY	HIV	\$343,627	3.4%	113	\$3,041	Y
4	MAVYRET*	Hepatitis C, Direct-Acting Antivirals	\$227,943	2.2%	22	\$10,361	Y
5	SUBLOCADE	Substance Use Disorders, Opioid & Alcohol	\$221,094	2.2%	115	\$1,923	Y
6	OZEMPIC*	Diabetes, GLP-1 Receptor Agonists and GIP The	\$191,960	1.9%	352	\$545	N
7	DAYBUE*	STC 99 - Miscellaneous	\$191,715	1.9%	9	\$21,302	N
8	Injection, Ocrelizumab, 1 Mg	Physican Administered Drug	\$189,575	1.9%	12	\$15,798	
9	HUMIRA(CF) PEN*	Targeted Immune Modulators	\$177,021	1.7%	38	\$4,658	Y
10	Daratumumab, Hyaluronidase	Physican Administered Drug	\$170,197	1.7%	32	\$5,319	
11	JARDIANCE	Diabetes, SGLT-2 Inhibitors	\$151,602	1.5%	393	\$386	Y
12	FINTEPLA*	Antiepileptics, Outpatient	\$138,414	1.4%	14	\$9,887	N
13	Canakinumab Injection	Physican Administered Drug	\$122,700	1.2%	3	\$40,900	
14	TRIKAFTA*	Cystic Fibrosis	\$116,832	1.1%	25	\$4,673	N
15	EVEROLIMUS*	Antineoplastics, Newer	\$115,949	1.1%	13	\$8,919	
16	ELIQUIS	Anticoagulants, Oral and SQ	\$112,069	1.1%	292	\$384	Y
17	TRULICITY*	Diabetes, GLP-1 Receptor Agonists and GIP The	\$99,439	1.0%	167	\$595	Y
18	IBRANCE*	Antineoplastics, Newer	\$98,855	1.0%	5	\$19,771	
19	Aflibercept Injection	Physican Administered Drug	\$97,446	1.0%	270	\$361	
20	IMCIVREE*	Weight Management Drugs	\$96,401	0.9%	3	\$32,134	
21	TALTZ AUTOINJECTOR*	Targeted Immune Modulators	\$94,492	0.9%	13	\$7,269	Y
22	EPIDIOLEX*	Antiepileptics, Outpatient	\$88,707	0.9%	74	\$1,199	N
23	KISQALI*	Antineoplastics, Newer	\$87,586	0.9%	7	\$12,512	
24	ALYFTREK*	Cystic Fibrosis	\$85,275	0.8%	5	\$17,055	N
25	MOUNJARO*	Diabetes, GLP-1 Receptor Agonists and GIP The	\$76,878	0.8%	132	\$582	N
26	ADVATE	Antihemophilia Factors	\$76,398	0.7%	3	\$25,466	
27	Altuviiio Per Factor Viii Iu	Physican Administered Drug	\$76,253	0.7%	1	\$76,253	
28	COSENTYX SENSOREADY (2 PENS)*	Targeted Immune Modulators	\$74,412	0.7%	14	\$5,315	N
29	BRIXADI	Substance Use Disorders, Opioid & Alcohol	\$71,685	0.7%	42	\$1,707	Y
30	Inj, Faricimab-Svoa, 0.1mg	Physican Administered Drug	\$70,136	0.7%	140	\$501	
31	LISDEXAMFETAMINE DIMESYLATE*	ADHD Drugs	\$67,049	0.7%	831	\$81	Y
32	BUPRENORPHINE-NALOXONE*	Substance Use Disorders, Opioid & Alcohol	\$66,125	0.6%	1,029	\$64	Y
33	SKYRIZI*	Targeted Immune Modulators	\$64,990	0.6%	4	\$16,248	N
34	Mifepristone, Oral, 200 Mg	Physican Administered Drug	\$60,845	0.6%	768	\$79	
35	STELARA*	Targeted Immune Modulators	\$59,952	0.6%	18	\$3,331	N
36	Etonogestrel Implant System	Physican Administered Drug	\$59,658	0.6%	81	\$737	
37	COSENTYX SYRINGE*	Targeted Immune Modulators	\$59,433	0.6%	5	\$11,887	N
38	PAXLOVID	Coronavirus Antivirals	\$58,960	0.6%	47	\$1,254	Y
39	DEXCOM G7 SENSOR*	Diabetic Supplies, CGM	\$55,608	0.5%	256	\$217	Y
40	ALBUTEROL SULFATE HFA	Beta-Agonists, Inhaled Short-Acting	\$55,248	0.5%	2,111	\$26	Y
Top 40 Aggregate:			\$5,044,746		7,520	\$12,643	
All FFS Drugs Totals:			\$10,200,007		100,704	\$643	

* Drug requires Prior Authorization

Notes

- FFS Drug Gross Costs only, rebates not subtracted
- PDL Key: Y=Preferred, N=Non-Preferred, V=Voluntary, Blank=Non PDL Class
- Amount Paid on the Claim = 1) Ingredient Cost ((AAAC/NADAC/WAC) x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount